Alcohol pretreatment of stools effect on culturomics

[1]  T. Vatanen,et al.  The Super-Donor Phenomenon in Fecal Microbiota Transplantation , 2019, Front. Cell. Infect. Microbiol..

[2]  V. Young,et al.  Novel therapies and preventative strategies for primary and recurrent Clostridium difficile infections , 2018, Annals of the New York Academy of Sciences.

[3]  Xiaokang Wu,et al.  Molecular Alteration Analysis of Human Gut Microbial Composition in Graves' disease Patients , 2018, International journal of biological sciences.

[4]  J. Wargo,et al.  The gut microbiota influences anticancer immunosurveillance and general health , 2018, Nature Reviews Clinical Oncology.

[5]  I. Beales,et al.  Comparison of Different Strategies for Providing Fecal Microbiota Transplantation to Treat Patients with Recurrent Clostridium difficile Infection in Two English Hospitals: A Review , 2018, Infectious Diseases and Therapy.

[6]  S. Delgado,et al.  Bifidobacteria and Their Molecular Communication with the Immune System , 2017, Front. Microbiol..

[7]  R. Guerrant,et al.  A randomized controlled trial of probiotics for Clostridium difficile infection in adults (PICO) , 2017, The Journal of antimicrobial chemotherapy.

[8]  Yongzheng Peng,et al.  Phascolarctobacterium faecium abundant colonization in human gastrointestinal tract. , 2017, Experimental and therapeutic medicine.

[9]  C. Robert,et al.  Culture of previously uncultured members of the human gut microbiota by culturomics , 2016, Nature Microbiology.

[10]  M. Henn,et al.  A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevents Recurrent Clostridium difficile Infection. , 2016, The Journal of infectious diseases.

[11]  F. Bäckhed,et al.  Microbiota-Produced Succinate Improves Glucose Homeostasis via Intestinal Gluconeogenesis. , 2016, Cell metabolism.

[12]  Nitin Kumar,et al.  Culturing of ‘unculturable’ human microbiota reveals novel taxa and extensive sporulation , 2016, Nature.

[13]  Nora C. Toussaint,et al.  Loss of Microbiota-Mediated Colonization Resistance to Clostridium difficile Infection With Oral Vancomycin Compared With Metronidazole. , 2015, The Journal of infectious diseases.

[14]  D. Raoult,et al.  Dramatic reduction in Clostridium difficile ribotype 027-associated mortality with early fecal transplantation by the nasogastric route: a preliminary report , 2015, European Journal of Clinical Microbiology & Infectious Diseases.

[15]  Antonio Ramos,et al.  Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial. , 2015, JAMA.

[16]  Lisa G Winston,et al.  Burden of Clostridium difficile Infection in the United States , 2015 .

[17]  B. Weimer,et al.  Gut microbiota-produced succinate promotes C. difficile infection after antibiotic treatment or motility disturbance. , 2014, Cell host & microbe.

[18]  Adolfo Suárez,et al.  Intestinal microbiota in health and disease: role of bifidobacteria in gut homeostasis. , 2014, World journal of gastroenterology.

[19]  J. Chun,et al.  Towards a taxonomic coherence between average nucleotide identity and 16S rRNA gene sequence similarity for species demarcation of prokaryotes. , 2014, International Journal of Systematic and Evolutionary Microbiology.

[20]  M. Tvede,et al.  Faecal microbiota transplantation and bacteriotherapy for recurrent Clostridium difficile infection: A retrospective evaluation of 31 patients , 2014, Scandinavian journal of infectious diseases.

[21]  M. Gueimonde,et al.  Interactions between Bifidobacterium and Bacteroides Species in Cofermentations Are Affected by Carbon Sources, Including Exopolysaccharides Produced by Bifidobacteria , 2013, Applied and Environmental Microbiology.

[22]  J. Holt,et al.  Fecal Microbiota Transplantation and Emerging Treatments for Clostridium difficile Infection , 2013, Journal of pharmacy practice.

[23]  L. Brandt.  American Journal of Gastroenterology Lecture: Intestinal Microbiota and the Role of Fecal Microbiota Transplant (FMT) in Treatment of C. difficile Infection , 2013, The American Journal of Gastroenterology.

[24]  E. Zoetendal,et al.  Duodenal infusion of donor feces for recurrent Clostridium difficile. , 2013, The New England journal of medicine.

[25]  G. Gloor,et al.  Stool substitute transplant therapy for the eradication of Clostridium difficile infection: ‘RePOOPulating’ the gut , 2013, Microbiome.

[26]  C. Robert,et al.  The gut microbiota of a patient with resistant tuberculosis is more comprehensively studied by culturomics than by metagenomics , 2013, European Journal of Clinical Microbiology & Infectious Diseases.

[27]  D Raoult,et al.  Microbial culturomics: paradigm shift in the human gut microbiome study. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[28]  K. Kirkland,et al.  Patient attitudes toward the use of fecal microbiota transplantation in the treatment of recurrent Clostridium difficile infection. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  A. Khoruts,et al.  Standardized Frozen Preparation for Transplantation of Fecal Microbiota for Recurrent Clostridium difficile Infection , 2012, The American Journal of Gastroenterology.

[30]  Michael A Fischbach,et al.  Eating for two: how metabolism establishes interspecies interactions in the gut. , 2011, Cell host & microbe.

[31]  J. Jansson,et al.  Changes in the Composition of the Human Fecal Microbiome After Bacteriotherapy for Recurrent Clostridium difficile-associated Diarrhea , 2009, Journal of clinical gastroenterology.

[32]  D. Raoult,et al.  Ongoing revolution in bacteriology: routine identification of bacteria by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[33]  R. Tanaka,et al.  Dialister succinatiphilus sp. nov. and Barnesiella intestinihominis sp. nov., isolated from human faeces. , 2008, International journal of systematic and evolutionary microbiology.

[34]  L. De Vuyst,et al.  Kinetic Analysis of Bifidobacterial Metabolism Reveals a Minor Role for Succinic Acid in the Regeneration of NAD+ through Its Growth-Associated Production , 2006, Applied and Environmental Microbiology.

[35]  Stuart Johnson,et al.  An epidemic, toxin gene-variant strain of Clostridium difficile. , 2005, The New England journal of medicine.

[36]  Ken Dewar,et al.  A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. , 2005, The New England journal of medicine.

[37]  Louis Valiquette,et al.  Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity , 2004, Canadian Medical Association Journal.

[38]  H. Harmsen,et al.  Growth requirements and fermentation products of Fusobacterium prausnitzii, and a proposal to reclassify it as Faecalibacterium prausnitzii gen. nov., comb. nov. , 2002, International journal of systematic and evolutionary microbiology.

[39]  E. Stackebrandt,et al.  Phascolarctobacterium faecium gen. nov, spec. nov., a Novel Taxon of the Sporomusa Group of Bacteria , 1993 .

[40]  J. Rask-Madsen,et al.  BACTERIOTHERAPY FOR CHRONIC RELAPSING CLOSTRIDIUM DIFFICILE DIARRHOEA IN SIX PATIENTS , 1989, The Lancet.

[41]  V. R. Dowell,et al.  Use of ethanol for selective isolation of sporeforming microorganisms , 1978, Applied and environmental microbiology.

[42]  R. C. Macridis.  A review , 1963 .

[43]  M. Tvede,et al.  Rectal bacteriotherapy for recurrent Clostridium difficile-associated diarrhoea: results from a case series of 55 patients in Denmark 2000-2012. , 2015, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[44]  E. Stackebrandt.  Taxonomic parameters revisited : tarnished gold standards , 2006 .

[45]  E. Glaser.  The randomized clinical trial. , 1972, The New England journal of medicine.

[46]  M. Sherman,et al.  A Preliminary Report , 1953 .